Guardant Health, Inc. $GH Stock: China Universal Asset Management Co. Ltd. Boosts Stake

China Universal Asset Management Co. Ltd. grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 16.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,486 shares of the company’s stock after buying an additional 3,383 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Guardant Health were worth $4,352,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Motley Fool Asset Management LLC lifted its holdings in shares of Guardant Health by 45.9% in the 3rd quarter. Motley Fool Asset Management LLC now owns 3,399 shares of the company’s stock valued at $606,000 after acquiring an additional 1,069 shares during the last quarter. North Dakota State Investment Board increased its stake in Guardant Health by 4.3% during the third quarter. North Dakota State Investment Board now owns 3,914 shares of the company’s stock worth $698,000 after acquiring an additional 163 shares during the last quarter. Simplify Asset Management Inc. increased its stake in Guardant Health by 77.5% during the third quarter. Simplify Asset Management Inc. now owns 48,940 shares of the company’s stock worth $8,729,000 after acquiring an additional 21,369 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in Guardant Health during the third quarter worth approximately $371,000. Finally, Oppenheimer & Co. Inc. increased its position in shares of Guardant Health by 50.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,561 shares of the company’s stock valued at $1,349,000 after purchasing an additional 2,525 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Guardant Health

In other Guardant Health news, CTO Darya Chudova sold 7,738 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the sale, the chief technology officer owned 70,635 shares of the company’s stock, valued at approximately $12,573,030. This trade represents a 9.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 37,500 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the sale, the chief executive officer directly owned 37,500 shares in the company, valued at $6,343,500. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 178,940 shares of company stock valued at $30,070,911 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ GH opened at $185.31 on Friday. The firm’s 50 day moving average price is $169.49 and its 200-day moving average price is $130.33. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05. The company has a market cap of $24.87 billion, a PE ratio of -53.10 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. The business’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.44) earnings per share. On average, analysts forecast that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. Stephens increased their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Guardant Health in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.